Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

ClinicalTrials.gov ID: NCT06029426

Public ClinicalTrials.gov record NCT06029426. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 13, 2026, 2:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a randomized, double blind, placebo controlled, multi-center study to evaluate the effects of NMRA-335140 (formerly BTRX 335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an extension study (NMRA-335140 501).

Study identification

NCT ID
NCT06029426
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Enrollment
383 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 19, 2023
Primary completion
Dec 2, 2024
Completion
Jan 14, 2025
Last update posted
Nov 25, 2025

2023 – 2025

United States locations

U.S. sites
64
U.S. states
20
U.S. cities
59
Facility City State ZIP Site status
Neumora Investigator Site Huntsville Alabama 35801
Neumora Investigator Site Phoenix Arizona 85012
Neumora Investigator Site Bentonville Arkansas 72712
Neumora Investigator Site-1 Little Rock Arkansas 72211
Neumora Investigator Site Little Rock Arkansas 72211
Neumora Investigator Site Rogers Arkansas 72758
Neumora Investigator Site Bellflower California 90706
Neumora Investigator Site Garden Grove California 92845
Neumora Investigator Site Glendale California 91206
Neumora Investigator Site Imperial California 92251
Neumora Investigator Site Lafayette California 94549
Neumora Investigator Site Long Beach California 90807
Neumora Investigator Site Los Angeles California 90015
Neumora Investigator Site Oceanside California 92056
Neumora Investigator Site Orange California 92868
Neumora Investigator Site Riverside California 92506
Neumora Investigator Site San Jose California 95124
Neumora Investigator Site #1 Sherman Oaks California 91403
Neumora Investigator Site Sherman Oaks California 91403
Neumora Investigator Site Temecula California 92591
Neumora Investigator Site Torrance California 90504
Neumora Investigator Site Colorado Springs Colorado 80910
Neumora Investigator Site Gainesville Florida 32607
Neumora Investigator Site Hallandale Florida 33009
Neumora Investigator Site Jacksonville Florida 32256
Neumora Investigator Site Lauderhill Florida 33319
Neumora Investigator Site Maitland Florida 32751
Neumora Investigator Site Miami Florida 33122
Neumora Investigator Site Miami Florida 33125
Neumora Investigator Site Miami Florida 33183
Neumora Investigator Site Miami Lakes Florida 33016
Neumora Investigator Site Orlando Florida 32801
Neumora Investigator Site Tampa Florida 33607
Neumora Investigator Site Marietta Georgia 30060
Neumora Investigator Site Chicago Illinois 60634
Neumora Investigator Site Evanston Illinois 60201
Neumora Investigator Site Warrenville Illinois 60555
Neumora Investigator Site Boston Massachusetts 02116
Neumora Investigator Site Methuen Massachusetts 01844
Neumora Investigator Site Watertown Massachusetts 02472
Neumora Investigator Site Bloomfield Hills Michigan 48302
Neumora Investigator Site Flowood Mississippi 39232
Neumora Investigator Site Saint Charles Missouri 63304
Neumora Investigator Site Las Vegas Nevada 89102
Neumora Investigator Site Brooklyn New York 11224
Neumora Investigator Site Cedarhurst New York 11516
Neumora Investigator Site New York New York 10036
Neumora Investigator Site Staten Island New York 10314
Neumora Investigator Site Cleveland Ohio 44106
Neumora Investigator Site Columbus Ohio 43210
Neumora Investigator Site Dayton Ohio 45417
Neumora Investigator Site Garfield Heights Ohio 44125
Neumora Investigator Site Allentown Pennsylvania 18104
Neumora Investigator Site Media Pennsylvania 19063
Neumora Investigator Site Plymouth Meeting Pennsylvania 19462
Neumora Investigator Site Memphis Tennessee 38119
Neumora Investigator Site Austin Texas 78737
Neumora Investigator Site Dallas Texas 75235
Neumora Investigator Site Houston Texas 77030
Neumora Investigator Site Houston Texas 77090
Neumora Investigator Site Wichita Falls Texas 76309
Neumora Investigator Site Charlottesville Virginia 22903
Neumora Investigator Site Bellevue Washington 98007
Neumora Investigator Site Everett Washington 98201

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06029426, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 25, 2025 · Synced Sep 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06029426 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →